Molecular diagnostics devices market seen reaching $48.84 billion by 2030

The molecular diagnostics devices and equipment market is projected to grow from $27.23 billion in 2025 to $48.84 billion by 2030, according to The Business Research Company. Asia-Pacific led the market in 2025, while PCR, next-generation sequencing and automation are among the main technologies shaping demand.

Why it matters: - Molecular diagnostics devices are central to infectious disease testing, genetic screening and more targeted treatment decisions. - The market’s projected 12.7% CAGR through 2030 points to sustained demand across hospitals, labs and decentralized testing sites. - Rising disease detection needs and precision medicine adoption are expanding the role of molecular testing in routine care.

What happened: - The Business Research Company released its Molecular Diagnostics Devices And Equipment Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on August 18, 2026. - The report puts the market at $27.23 billion in 2025 and $30.33 billion in 2026. - The forecast calls for the market to reach $48.84 billion by 2030. - Asia-Pacific was the largest regional market in 2025. - Asia-Pacific is also expected to be the fastest-growing region over the forecast period.

The details: - The market grew on the back of infectious disease testing, broader genetic screening programs, more use in cancer care, improved sequencing accuracy and greater clinical awareness of molecular testing. - Future growth is tied to personalized medicine, higher investment in genomic diagnostics, more decentralized molecular testing facilities, automated sample processing and a stronger focus on early disease detection. - The report highlights PCR-based testing platforms, next-generation sequencing, diagnostic software, bioinformatics tools, companion diagnostics and early personalized diagnosis as key trends. - Molecular diagnostics devices detect specific DNA or RNA sequences to identify infectious diseases and support genetic screening. - The technology helps clinicians choose more precise and targeted therapies, especially early in illness. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report is available here. - The full report is available here.

Between the lines: - The market outlook reflects a shift from broad diagnostics toward faster, more precise and software-enabled testing workflows. - Infectious disease pressure is still a key demand driver, but oncology, genomics and companion diagnostics are becoming more important growth engines. - The regional lead for Asia-Pacific suggests manufacturing, testing capacity and healthcare investment are likely concentrated there. - U.S. tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, while the incidence rate increased from 2.5 to 2.9 per 100,000 people, underscoring the continued need for molecular testing.

What's next: - Molecular diagnostics companies are likely to keep investing in PCR, sequencing, automation and analytics tools. - Decentralized testing models should expand as providers look for faster results and broader access. - Demand for early detection and personalized medicine could keep the market on a double-digit growth path beyond 2030. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, key technologies and updated graphics and tables.

The bottom line: - Molecular diagnostics is moving deeper into mainstream care, and the market outlook suggests that shift still has room to run.